Bone Biologics (BBLG) Cash & Equivalents (2012 - 2025)

Bone Biologics (BBLG) has 14 years of Cash & Equivalents data on file, last reported at $5.3 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $5.3 million, up 60.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.3 million (up 60.42% YoY), and the FY2025 annual result was $5.3 million, up 60.42% from the prior year.
• Cash & Equivalents slipped to $5.3 million in Q4 2025 per BBLG's latest filing, from $6.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $7.5 million in Q4 2022 and troughed at $3374.0 in Q3 2021.
• A 5-year average of $4.2 million and a median of $4.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 149847.93% in 2022, then plunged 66.72% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $6.7 million in 2021, then increased by 12.93% to $7.5 million in 2022, then plunged by 59.85% to $3.0 million in 2023, then advanced by 9.86% to $3.3 million in 2024, then jumped by 60.42% to $5.3 million in 2025.
• Business Quant data shows BBLG's Cash & Equivalents at $5.3 million in Q4 2025, $6.0 million in Q3 2025, and $6.6 million in Q2 2025.